Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos rna

Human Gene Therapy

Volumn 7, Issue 11, 1996, Pages 1367-1380

  Holt, Jeffrey T ^a   Arteaga, Carlos B ^b   Robertson, David ^b   Moses, Harold L ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; PROTEIN C FOS;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST; BREAST TUMOR; CLINICAL PROTOCOL; FEMALE; GENE THERAPY; GENE VECTOR; GENETIC TRANSFORMATION; GENETICS; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; RETROVIRUS;

ADOLESCENT; ADULT; AGED; BREAST; BREAST NEOPLASMS; CLINICAL PROTOCOLS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-FOS; RETROVIRIDAE; RNA, ANTISENSE; TRANSFORMATION, GENETIC;

EID: 0030578220     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.11-1367     Document Type: Article

References (40)

1. Dupont WD, DL Page, LW Rogers, and FF Pari. 1989. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 63:948-957.
2. Weed DL, P Greenwald, and JW Cullem. 1990. The future of cancer prevention and control. Semin. Oncol. 17:504-509.
3. Lippman SM, JS Lee, R Lotan, W Hittelman, MJ Wargovich, and WK Hong. 1990. Biomarkers as intermediate endpoints in chemoprevention trials. JNCI 82:555-560.
4. Callahan R, CS Cropp, OR Merlo, DS Liscia, APM Cappa, and R Lidereau. 1992. Somatic mutations and human breast cancer. Cancer 69:1582-86.
5. Cheickh MB, P Rouanet, G Louason, P Jeanteur, and C Theillet. 1992. An attempt to define sets of cooperating genetic alterations in human breast cancer. Int. J. Cancer 51:542-547.
6. Chen L-C, W Kurisu, B-M Ljung, ES Goldman, Dmorre II, and HS Smith. 1992. Heterogeneity for allelic loss in human breast cancer. JNCI 84:506-510.
7. Poller, D.N., C.E. Hutchings, et al. 1992. p53 Protein expression in human breast carcinoma: Relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583-588.
8. Allred, D.C., G.M. Clark, et al. 1992. Overexpression of HER2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23(9): 974-979.
9. Borg A, B Baldetorp, M Ferno, H Olsson, and H Sigurdsson. Cmyc amplification is an independent prognostic factor in postmenopausal breast cancer. Int. J. Cancer 51:687-691, 1992.
10. Komitowski D, and C. Janson. 1990. Quantitative features of chromatin structure in the prognosis of breast cancer. Cancer 65:2725-2730.
11. Cato, A.C., Weinmann, J., Mink, S., Ponta, H., Henderson, D. and Sonnenberg, A.: The regulation of expression of mouse mammary tumor virus DNA by steroid hormones and growth factors. J. Steroid Biochem. 34: 139, 1989.
12. Choi, Y., Henrard, D., Lee, I. and Ross, S.R.: The mouse mammary tumor virus long terminal repeat directs expression in epithelial and lymphoid cells of different tissues in transgenic mice. J. Virol., 61:3013, 1987.
13. Matsui, Y., Halter, S.A., Holt, J.T., Hogan, B.L.M. and Coffey, R.J., Jr.: Development of mammary hyperplasia and neoplasia in MMTV-TGFa transgenic mice. Cell, 61:1147, 1990.
14. Jhappan, C., Stahle, C, Harkins, R.N., Fausto, N., Smith, G.M. and Merlino, G.T.: TGFa overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 61:1137, 1990.
15. Halter, S.A., Dempsey, P., Matsui, Y., Stokes, M.K., Graves-Deal, R., Hogan, B.L.M. and Coffey, R.J., Jr.: Distinctive patterns of hyperplasia in MMTV-TGFa transgenic mice. Characterization of mammary gland and skin proliferations. Am. J. Pathol., 140:1131, 1992.
16. Sinn E, Muller W, P Pattengale, I Tepler, R Wallace, and P Leder. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic actions of oncogenes in vivo. Cell 49:465-75, 1987.
17. Muller WJ, E Sinn, PK Pattengale, R Wallace, and P Leder. Singlestep induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1988.
18. Fearon ER and B Vogelstein. A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
19. Holt JT, Redner RL, and Nienhuis AW. An oligomer complementary to c-myc inhibits proliferation of HL60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. 8:963-974, 1988.
20. Sawyers CL, W Callahan, and ON Witte. Dominant negative myc blocks transformation by abl oncogenes. Cel 70:901-910, 1992.
21. Huang H-JS, Yee J-K, Shew J-Y, Chen PL et al. (WH Lee) Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science 242:1563-1566, 1988.
22. Holt, J.T., Gopal, T.V., Moulton, A.D. and Nienhuis, A.W.: Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. Proc. Natl. Acad. Sei. USA, 83:4794, 1986.
23. Nishikura, K., and J.M. Murray. 1987. Antisense RNA of protooncogene c-fos blocks renewed growth of quiescent 3T3 cells. Mol. Cell. Biol. 7:639-649.
24. Wong PMC, Karlsson S, Holt JT, Redner RL, Turner P, and Nienhuis AW. Transfer of Genes into Hematopoietic Cells Using Retroviral Vectors. In: Proceedings of the UCLA symposia on Biology of Leukemia and Lymphomas. Golde D. (ed.), Alan R. Liss, Inc. 61:553-566, 1988.
25. Holt, JT. Antisense rescue defines Specialized and Generalized functions for c-fos protein during cell growth. Mol. Cell. Biol. 13:3821-3820, 1993.
26. Holt JT. Growth Inhibition by Antisense Nucleic Acids. In: Discoveries in Antisense Nucleic Acids. Brakel C. (ed.), Gulf Press. 2:81-94, 1989.
27. Kerr, L.D., J.T. Holt, and L.M. Matrisian. 1988. Growth factors regulate transin gene expression by c-fos dependent and c-fos independent pathways. Science 242:1424-1427.
28. Kirn S-J., F Denhez, K-Y Kim, JT Holt, MB Sporn, and AB Roberts. Activation of the second promoter of the TGF-betal gene by TGF-betal and phorbol ester occurs through the same target sequences. J. Biol. Chem. 264:19373-19378, 1989.
29. Kovary, K., and R. Bravo. 1991. The Jun and Fos protein families are both required for cell cycle progression in fibroblasts. Mol. Cell. Biol. 11:4466-4472.
30. Robinson-Benion, C., Salhany, K.E., Kann, S.R., and Holt, J.T.: Antisense inhibition of c-myc expression reveals common and distinct mechanisms of growth inhibition by TGFjS and TGFc. J. Cell. Biochem., 45:188, 1991.
31. Momand J, GP Zambetti, DC Olsen, D George, and AJ Levine. The mdm-2 oncogene product forms a complex with the p53 pro-tein and inhibits p53-mediated transformation. Cell 69:1237-1245, 1992.
32. Johnson, R.S., B.M. Spiegelman, and V. Papaioannou. 1992. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71:577-586.
33. Field, S., R.S. Johnson, R. Mortenson, V.E. Papaioannou, B.M. Spiegelman, and M.E. Greenberg. 1992. Fos is not required for the growth or differentiation of ES cells. Proc. Natl. Acad. Sei. USA 89:9306-9310.
34. Munger, K., J.A. Pietenpol, M.A. Pittelkow, J.T. Holt, and H.L. Moses. TGFbeta regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth and Differentiation 3:291-298, 1992.
35. Pietenpol JA, JT Holt, RW Stein, and HL Moses. TGF-betal suppression of c-myc gene transcription inhibits keratinocyte proliferation. Proc. Natl. Acad. Sei. USA. 87:3758-3762, 1990.
36. Pietenpol JA, RW Stein, E Moran, P Yaciuk, et al. TGF-Betal inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61:777-785, 1990.
37. Moscionio, AD, J Rozga, DF Neuzil, RW Overell, JT Holt, and AA Demetriou. In vivo regional delivery of retrovirally mediated foreign genes to rat liver cells: need for partial hepatectomy for successful foreign gene expression. Surgery 113:304-311, 1993.
38. Ram Z, S Walbridge, EM Oshiro, JJ Viola, Y Chiang, SN Mueller, RM Blaese, and EH Oldfield. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res. 54:2141-2145, 1994.
39. Miller AD, DG Miller, JV Garcia, and CM Lynch. Use of retroviral vectors for gene transfer and expression. Methods in Enzym. 217:581-599.
40. Arteaga CL and JT Holt. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res. 56:1098-1103, 1996.